784.61 USD
-2.71 (-0.34%)
788 USD
+3.39 (+0.43%)
Overall REGN gets a fundamental rating of 6 out of 10. We evaluated REGN against 533 industry peers in the Biotechnology industry. REGN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. REGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
REGN had positive earnings in the past year.
REGN had a positive operating cash flow in the past year.
REGN had positive earnings in each of the past 5 years.
In the past 5 years REGN always reported a positive cash flow from operatings.
1.2 Ratios
REGN's Return On Assets of 11.40% is amongst the best of the industry. REGN outperforms 94.37% of its industry peers.
With an excellent Return On Equity value of 14.79%, REGN belongs to the best of the industry, outperforming 94.93% of the companies in the same industry.
REGN's Return On Invested Capital of 8.69% is amongst the best of the industry. REGN outperforms 94.18% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for REGN is significantly below the industry average of 18.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROIC | 8.69% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
1.3 Margins
REGN's Profit Margin of 32.13% is amongst the best of the industry. REGN outperforms 96.62% of its industry peers.
In the last couple of years the Profit Margin of REGN has grown nicely.
The Operating Margin of REGN (27.61%) is better than 96.44% of its industry peers.
REGN's Operating Margin has declined in the last couple of years.
REGN has a Gross Margin of 86.28%. This is amongst the best in the industry. REGN outperforms 88.18% of its industry peers.
REGN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% |
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for REGN remains at a similar level compared to 1 year ago.
Compared to 5 years ago, REGN has less shares outstanding
REGN has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 7.72 indicates that REGN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.72, REGN is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
REGN has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
REGN has a Debt to FCF ratio of 0.70. This is amongst the best in the industry. REGN outperforms 94.37% of its industry peers.
REGN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.09, REGN is not doing good in the industry: 62.10% of the companies in the same industry are doing better.
Although REGN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 7.72 |
ROIC/WACC1.03
WACC8.42%
2.3 Liquidity
REGN has a Current Ratio of 4.06. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN has a Current ratio (4.06) which is in line with its industry peers.
REGN has a Quick Ratio of 3.51. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.51, REGN is in line with its industry, outperforming 44.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 |
3. Growth
3.1 Past
The earnings per share for REGN have decreased by -0.92% in the last year.
Measured over the past years, REGN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.12% on average per year.
Looking at the last year, REGN shows a small growth in Revenue. The Revenue has grown by 2.89% in the last year.
REGN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.55% yearly.
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
3.2 Future
The Earnings Per Share is expected to grow by 6.65% on average over the next years.
REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.75% yearly.
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.65%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.75%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.43, the valuation of REGN can be described as rather expensive.
94.75% of the companies in the same industry are more expensive than REGN, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.15, REGN is valued a bit cheaper.
A Price/Forward Earnings ratio of 17.66 indicates a rather expensive valuation of REGN.
94.37% of the companies in the same industry are more expensive than REGN, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 36.12. REGN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.43 | ||
| Fwd PE | 17.66 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, REGN is valued cheaply inside the industry as 94.75% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, REGN is valued cheaply inside the industry as 94.37% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.43 | ||
| EV/EBITDA | 16.03 |
4.3 Compensation for Growth
REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.33
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
5. Dividend
5.1 Amount
REGN has a yearly dividend return of 0.48%, which is pretty low.
Compared to an average industry Dividend Yield of 74.20, REGN pays a better dividend. On top of this REGN pays more dividend than 98.31% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.41, REGN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.48% |
5.2 History
REGN does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
784.61
-2.71 (-0.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners90.24%
Inst Owner Change-0.5%
Ins Owners1.89%
Ins Owner Change0.16%
Market Cap83.16B
Revenue(TTM)14.25B
Net Income(TTM)4.58B
Analysts80.59
Price Target774.53 (-1.28%)
Short Float %2.74%
Short Ratio2.61
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.48% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.37%
Min EPS beat(2)20.96%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)16.75%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.92%
EPS beat(12)10
Avg EPS beat(12)9.47%
EPS beat(16)13
Avg EPS beat(16)8.82%
Revenue beat(2)2
Avg Revenue beat(2)6.19%
Min Revenue beat(2)2.66%
Max Revenue beat(2)9.72%
Revenue beat(4)2
Avg Revenue beat(4)0.54%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.34%
Revenue beat(12)8
Avg Revenue beat(12)1.48%
Revenue beat(16)12
Avg Revenue beat(16)2.04%
PT rev (1m)3.97%
PT rev (3m)3.91%
EPS NQ rev (1m)13.36%
EPS NQ rev (3m)13.93%
EPS NY rev (1m)6.84%
EPS NY rev (3m)6.99%
Revenue NQ rev (1m)3.48%
Revenue NQ rev (3m)4.29%
Revenue NY rev (1m)1.81%
Revenue NY rev (3m)1.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.43 | ||
| Fwd PE | 17.66 | ||
| P/S | 5.84 | ||
| P/FCF | 21.43 | ||
| P/OCF | 16.4 | ||
| P/B | 2.69 | ||
| P/tB | 2.81 | ||
| EV/EBITDA | 16.03 |
EPS(TTM)45.01
EY5.74%
EPS(NY)44.42
Fwd EY5.66%
FCF(TTM)36.62
FCFY4.67%
OCF(TTM)47.84
OCFY6.1%
SpS134.43
BVpS292.08
TBVpS279.05
PEG (NY)N/A
PEG (5Y)1.33
Graham Number543.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 11.4% | ||
| ROE | 14.79% | ||
| ROCE | 11.01% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 11.99% | ||
| OM | 27.61% | ||
| PM (TTM) | 32.13% | ||
| GM | 86.28% | ||
| FCFM | 27.24% |
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.44%
ROIC(5y)18.14%
ROICexc(3y)18.09%
ROICexc(5y)25.25%
ROICexgc(3y)19.06%
ROICexgc(5y)25.84%
ROCE(3y)15.75%
ROCE(5y)22.96%
ROICexgc growth 3Y-32.64%
ROICexgc growth 5Y-8.74%
ROICexc growth 3Y-33.7%
ROICexc growth 5Y-9.6%
OM growth 3Y-19.71%
OM growth 5Y-2.68%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.28%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.61 | ||
| Cap/Depr | 226.62% | ||
| Cap/Sales | 8.35% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 113.73% | ||
| Profit Quality | 84.78% | ||
| Current Ratio | 4.06 | ||
| Quick Ratio | 3.51 | ||
| Altman-Z | 7.72 |
F-Score5
WACC8.42%
ROIC/WACC1.03
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.76%
Profit Quality(5y)77.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-0.92%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%-5.06%
EPS Next Y-6.32%
EPS Next 2Y-1.35%
EPS Next 3Y5.14%
EPS Next 5Y6.65%
Revenue 1Y (TTM)2.89%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%0.9%
Revenue Next Year-0.32%
Revenue Next 2Y2.42%
Revenue Next 3Y4.76%
Revenue Next 5Y5.75%
EBIT growth 1Y-6.18%
EBIT growth 3Y-22.95%
EBIT growth 5Y9.54%
EBIT Next Year-14.02%
EBIT Next 3Y4.25%
EBIT Next 5Y8.44%
FCF growth 1Y-10.97%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y-2.93%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%
REGENERON PHARMACEUTICALS / REGN FAQ
Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?
ChartMill assigns a fundamental rating of 6 / 10 to REGN.
What is the valuation status for REGN stock?
ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (REGN). This can be considered as Fairly Valued.
Can you provide the profitability details for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (REGN) has a profitability rating of 8 / 10.
Can you provide the expected EPS growth for REGN stock?
The Earnings per Share (EPS) of REGENERON PHARMACEUTICALS (REGN) is expected to decline by -6.32% in the next year.